Evaluation of the venous thromboembolic risk in medical patients;Evaluation du risque thromboembolique veineux en millieu medical

Therapie

Volumn 53, Issue 6, 1998, Pages 565-570

  Mismetti, P ^a   Juillard Delsart, D ^a   Tardy, B ^b   Laporte Simitsidis, S ^a   Decousus, H ^a  

^a University Jean Monnet of Saint Etienne EA3065   (France)

^b SERVICE DE NEUROLOGIE   (France)

Author keywords

Aspirin; Deep vein thrombosis; Heparins; Medical patients; Prophylaxis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; HUMAN; INCIDENCE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RISK; STROKE; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0032452618     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J Roy Soc Med 1989; 82: 198-200.
2. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992; 305: 567-574.
3. Anderson FA, Wheeler HB, Goldberg RJ et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med 1991; 151: 933-938.
4. Cogo A, Bernardi E, Prandoni P et al. Acquired risk factors for deep vein thrombosis in symptomatic outpatients. Arch Intern Med 1994; 154: 164-168.
5. Councell C, Sandercock P. The efficacy and safety of anticoagulant therapy in patients with acute presumed ischaemic stroke: a systematic review of the randomised trials comparing anticoagulants with control. In: Warlow C, Van Gijn J, Sandercock P, eds. The Cochrane Database Library. Cochrane Collaboration; issue 1. Oxford: Update Software, 1997.
6. Collins R, MacMahon S, Flather M et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 1996; 313: 652-659.
7. Mismetti P, Laporte S, Tardy B et al. Prevention of venous thrombo-embolism in internal medicine. A meta-analysis of randomised trials. Submitted for publication.
8. Antiplatelet Trialist's Collaboration. Collaborative overnew of randomised trials of antiplatelets therapy, I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
9. Bern M, Lokich J, Wallach S et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 1990; 112: 423-428.
10. Levine M, Hirsh J, Gent M et al. Double blind randomised trial of very low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-889.
11. Clagett GP, Anderson FA, Heilt J et al. Prevention of venous thromboembolism. CHEST 1995; 108: 312S-334S.
12. International Consensus Statement. Prevention of venous thromboembolism. International Angiology 1997; 16: 3-38.
13. Kay R, Wong KS, Lu YL et al. Low-molecular-weight heparin for the treatment of acute ischaemic stroke. N Engl J Med 1995; 333: 1588-1593.
14. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-1581.